Table 3 Treatment Patterns of Patients with AD (Entire Observation Period)

Filled prescriptions per year, mean ± SD | median

3.3 ± 4.3 | 1.8

2.0 ± 2.8 | 1.0

<0.001*

  ≤1 prescription, n (%)

75,572 (31.4)

120,996 (51.1)

<0.001*

 2–3 prescriptions, n (%)

87,804 (36.5)

73,057 (30.8)

<0.001*

  >3 prescriptions, n (%)

77,272 (32.1)

42,783 (18.1)

<0.001*

Combination therapy with ≥2 distinct AD treatments, n (%)

97,366 (40.5)

46,171 (19.5)

<0.001*

Topical treatments, n (%)

210,857 (87.6)

203,975 (86.1)

<0.001*

 Topical antihistamines

24 (0.0)

55 (0.0)

<0.001*

 Any topical corticosteroids (TCS)

210,094 (87.3)

200,975 (84.9)

<0.001*

  TCS low potency

100,439 (41.7)

74,010 (31.2)

<0.001*

  TCS medium potency

158,484 (65.9)

147,297 (62.2)

<0.001*

  TCS high potency

31,084 (12.9)

38,999 (16.5)

<0.001*

 Topical calcineurin inhibitors (TCI)

7998 (3.3)

17,579 (7.4)

<0.001*

Systemic antihistamines^a

170,511 (70.9)

51,817 (21.9)

<0.001*

  ≥1 sedating antihistamine

78,319 (32.5)

37,094 (15.7)

<0.001*

Systemic corticosteroids (SCS)^b

54,878 (22.8)

59,626 (25.2)

<0.001*

Any systemic immunosuppressants (IMM)

476 (0.2)

630 (0.3)

<0.001*

 Azathioprine

54 (0.0)

93 (0.0)

<0.001*

 Cyclosporine A

85 (0.0)

167 (0.1)

<0.001*

 Interferon gamma

0 (0.0)

1 (0.0)

–

 Methotrexate

261 (0.1)

339 (0.1)

<0.001*

 Mycophenolate mofetil

140 (0.1)

136 (0.1)

0.914

Intravenous immunoglobulin (IVIG)

2339 (1.0)

2784 (1.2)

<0.001*

Montelukast sodium^c

37,719 (15.7)

39,810 (16.8)

<0.001*

Phototherapy, n (%)

416 (0.2)

522 (0.2)

<0.001*